Yu Zhang
Executive Director Duality Biologics
Seminars
Tuesday 4th November 2025
Outlining Early Clinical Development of DB-1311/ BNT324 Targeting B7H3 in Advanced Solid Tumors
2:00 pm
- Introducing design and development of DB-1311 targeting B7-H3 immune checkpoint protein
- Exploring ongoing clinical development in Phase1/2 studies in patients with advanced solid tumors
- Highlighting future development plans and advantages from collaboration for global ADC clinical trials
